Health Care Equipment and Supplies Health Care Supplies

More

  • Johnson & Johnson reported higher-than-expected earnings as strong sales of prescription drugs and medical devices more than offset anemic growth of its consumer products.

  • Obama administration to scrap age restrictions on the sale of morning-after pills, making the emergency contraception available to women and girls of any age without a prescription.

  • Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.

  • US Healthcare

    Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.

  • Johnson & Johnson's stock has gained 22 percent on the year and trades at a higher P/E ratio than its competitors. It is not a good buy now, but a great hold, TheStreet.com says.

  • Health care insurance

    The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.

  • Johnson & Johnson products

    The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.

  • Entrepreneurs Capitalizing on Legalization of Marijuana

    Roger Parloff, Fortune senior editor, says businesses are sprouting in states like Colorado and Washington, where selling cannabis is now legal.

  • If you smoke, you might have to pay thousands extra for employee-based health insurance under Obamacare starting next year.

  • First on CNBC: Cochlear Earnings

    On a First on CNBC interview, Cochlear CEO Chris Roberts tells CashFlow about his company's products and plans for global expansion.

  • A Smart Bet on Johnson & Johnson?

    An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.

  • Pfizer Profit Drops on Loss of Lipitor Exclusivity

    Pfizer's unit Zoetis plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering.

  • One of the worst flu seasons in a decade is putting further strains on an already sluggish U.S. economy as companies get slammed with increased health care costs and lower productivity from widespread worker absences.

  • As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.

  • Health Care Needs More Entrepreneurs and Innovation: Google Ventures Head

    The managing partner of Google's venture capital, Bill Maris,  says under-investment in health sciences is short-sighted.

  • DNA

    The goal is to enable physicians and pharmaceutical companies to use complex genetic data to tailor treatment on an individual basis, according to Mike Pellini, CEO of Foundation Medical.

  • Fungal Meningitis Death Toll Reaches 8

    According to the CDC, the death toll has now reached 8 from a contaminated steroid used to treat back pain that came from a Massachusetts Compounding pharmacy. The next update from the CDC will be at 2PM EST today.

  • Paul_E._Jacobs-200.jpg

    Qualcomm's CEO Paul Jacobs says the smart phone will become a focal point for wirelessly connecting medical devices, diagnostics and sensors, and providing near real-time information.

  • Man with Alzheimer

    The aging of America is taking a toll on the health care system. By 2050, the cost of treating Alzheimer's patients will hit $1 trillion a year.

  • Doctor examining skin cancer

    Despite piles of research on the skin cancer risks of sun exposure and tanning beds, dermatologists and cancer groups struggle to persuade people to protect their skin from ultraviolet rays.